CoChat

DEAD-box helicase DP103 defines metastatic potential of human breast cancers

Open access
Shin, Eun Myoung, Sin Hay, Hui, Lee, Moon Hee, Goh, Jen Nee, Tan, Tuan Zea, Sen, Yin Ping, Lim, See Wee, Yousef, Einas M., Ong, Hooi Tin, Thike, Aye Aye, Kong, Xiangjun, Wu, Zhengsheng, Mendoz, Earnest, Sun, Wei, Salto-Tellez, Manuel, Lim, Chwee Teck, Lobie, Peter E., Lim, Yoon Pin, Yap, Celestial T., Zeng, Qi, Sethi, Gautam, Lee, Martin B., Tan, Patrick, Goh, Boon Cher, Miller, Lance D., Thiery, Jean Paul, Zhu, Tao, Gaboury, Louis, Tan, Puay Hoon, Hui, Kam Man, Yip, George Wai-Cheong, Miyamoto, Shigeki, Kumar, Alan Prem, Tergaonkar, Vinay · 2014 · Journal of Clinical Investigation
Cited by 132

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Despite advancement in breast cancer treatment, 30% of patients with early breast cancers experience relapse with distant metastasis. It is a challenge to identify patients at risk for relapse; therefore, the identification of markers and therapeutic targets for metastatic breast cancers is imperative. Here, we identified DP103 as a biomarker and metastasis-driving oncogene in human breast cancers and determined that DP103 elevates matrix metallopeptidase 9 (MMP9) levels, which are associated with metastasis and invasion through activation of NF-κB. In turn, NF-κB signaling positively activated DP103 expression. Furthermore, DP103 enhanced TGF-β-activated kinase-1 (TAK1) phosphorylation of NF-κB-activating IκB kinase 2 (IKK2), leading to increased NF-κB activity. Reduction of DP103 expression in invasive breast cancer cells reduced phosphorylation of IKK2, abrogated NF-κB-mediated MMP9 expression, and impeded metastasis in a murine xenograft model. In breast cancer patient tissues, elevated levels of DP103 correlated with enhanced MMP9, reduced overall survival, and reduced survival after relapse. Together, these data indicate that a positive DP103/NF-κB feedback loop promotes constitutive NF-κB activation in invasive breast cancers and activation of this pathway is linked to cancer progression and the acquisition of chemotherapy resistance. Furthermore, our results suggest that DP103 has potential as a therapeutic target for breast cancer treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci73451

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 132

Metadata

Authors
Shin, E. M., Sin Hay, H., Lee, M. H., Goh, J. N., Tan, T. Z., Sen, Y. P., Lim, S. W., Yousef, E. M., Ong, H. T., Thike, A. A., Kong, X., Wu, Z., Mendoz, E., Sun, W., Salto-Tellez, M., Lim, C. T., Lobie, P. E., Lim, Y. P., Yap, C. T., Zeng, Q., Sethi, G., Lee, M. B., Tan, P., Goh, B. C., Miller, L. D., Thiery, J. P., Zhu, T., Gaboury, L., Tan, P. H., Hui, K. M., Yip, G. W.-C., Miyamoto, S., Kumar, A. P., & Tergaonkar, V.
Venue
Journal of Clinical Investigation
Published
2014-08-01
Volume
124
Issue
9
Pages
3807-3824
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2106758941
Cited by
132
References
16
FWCI
2.43
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: DEAD-box helicase DP103 defines metastatic potential of human breast cancers. https://app.cochat.ai/papers/10.1172/jci73451
The paper
Shin, E. M., Sin Hay, H., Lee, M. H., Goh, J. N., Tan, T. Z., Sen, Y. P., Lim, S. W., Yousef, E. M., Ong, H. T., Thike, A. A., Kong, X., Wu, Z., Mendoz, E., Sun, W., Salto-Tellez, M., Lim, C. T., Lobie, P. E., Lim, Y. P., Yap, C. T., . . . Tergaonkar, V. (2014). DEAD-box helicase DP103 defines metastatic potential of human breast cancers. Journal of Clinical Investigation. https://doi.org/10.1172/jci73451

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.